Barrington analyst Michael Petusky maintained a Buy rating on VerifyMe (VRME – Research Report) today and set a price target of $1.70. The company’s shares closed yesterday at $1.12.
According to TipRanks, Petusky is a 4-star analyst with an average return of 7.4% and a 52.58% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, Haemonetics, and Lifecore Biomedical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for VerifyMe with a $2.85 average price target, representing a 154.46% upside. In a report released yesterday, Maxim Group also reiterated a Buy rating on the stock with a $4.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
VRME market cap is currently $11.09M and has a P/E ratio of -3.61.
Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VRME in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VerifyMe, Inc. engages in the provision of digital and physical solutions. It is able to deliver security solutions for identification and authentication of people, products and packaging in a variety of applications in the security field for physical transactions and owns digital patents which are in the same field. The company was founded by Norman A. Gardner on November 10, 1999 and is headquartered in Rochester, NY.
Read More on VRME:
